## Abstract Patients with newly diagnosed acute myeloid leukaemia (AML) are increasingly being enrolled in clinical trials sponsored by pharmaceutical companies or the National Cancer Institute. These trials routinely exclude patients who are less likely to respond (LLTR), e.g. those with Zubrod pe
Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia
β Scribed by Evelien L. J. Smits; Cindy Lee; Nicola Hardwick; Suzanne Brooks; Viggo F. I. Van Tendeloo; Kim Orchard; Barbara-ann Guinn
- Publisher
- Springer-Verlag
- Year
- 2011
- Tongue
- English
- Weight
- 243 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and AraβC and in phase II clinical trials has shown promising activ
a manifestation of lymphoma, and all died before receiving chemotherapy. If a patient with WM develops ascites, clinicians should consider the possibility that the disease has transformed into IL, especially if the patient has received alkylating agents.